CPX‑351 vs. FLAG‑ida in patients with high-risk AML/MDS and MDS-related gene mutations: a subgroup analysis of the UK NCRI AML19 trial

Priyanka Mehta; Roderick Murphy; Saemi Park; Stefan Faderl; Tomáš Skácel; Abin Thomas; Sean Johnson; Alex Legg

doi:10.1080/10428194.2026.2690155

July 1, 2026Leukemia & lymphoma/Leukemia and lymphoma

CPX‑351 vs. FLAG‑ida in patients with high-risk AML/MDS and MDS-related gene mutations: a subgroup analysis of the UK NCRI AML19 trial

View at Publisher

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Subgroup analysis evaluates efficacy of Cpx-351 vs. Flag-Ida in high-risk AML/MDS patients, suggesting implications for treatment.

Abstract

To the EditorWhile hematopoietic cell transplantation (HCT) offers the only curative potential for adults with high-risk acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) with MDS-rel...

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Mehta et al. (2026) studied this question.

synapsesocial.com/papers/6a48a23989561a0c2d78d0fa https://doi.org/10.1080/10428194.2026.2690155

View at Publisher

Ask AI

Bookmark

Share

CPX‑351 vs. FLAG‑ida in patients with high-risk AML/MDS and MDS-related gene mutations: a subgroup analysis of the UK NCRI AML19 trial

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

CPX‑351 vs. FLAG‑ida in patients with high-risk AML/MDS and MDS-related gene mutations: a subgroup analysis of the UK NCRI AML19 trial

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading